A US-based academic breast oncologist specialising in HER2-positive breast cancer management shares perspectives on neoadjuvant and adjuvant treatment strategies, the expanding role of trastuzumab deruxtecan (Enhertu) across disease settings, treatment sequencing in metastatic disease, reimbursement and insurance access in the US, and key areas of unmet need. The KOL also discusses emerging agents including zanidatamab (Ziihera), palbociclib (PATINA regimen), inavolisib (Itovebi), giredestrant, and vaccine immunotherapies (GLSI-100, Bria-IMT).

This interview was conducted on April 14, 2026.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.